Delving into the Latest Updates on Human Normal Immunoglobulin (Nihon Pharmaceutical Co., Ltd.) with Synapse

Overview

Basic Info

Drug Type

Immunoglobulin

Synonyms

Freeze dried Polyethylene Glycol Treated Human Normal Immunoglobulin, 乾燥ポリエチレングリコール処理人免疫グロブリン, 人血清アルブミン

+ [7]

Target-

Mechanism-

Therapeutic Areas

Hemic and Lymphatic DiseasesOther DiseasesImmune System Diseases+ [2]

Active Indication

HypoalbuminemiaShock, HemorrhagicHashimoto's Encephalitis

Inactive Indication

AQP4-IgG positive Neuromyelitis optica spectrum disorderGuillain-Barre SyndromeMultifocal Motor Neuropathy+ [2]

Originator Organization

Nihon Pharmaceutical Co., Ltd.

Active Organization

Nihon Pharmaceutical Co., Ltd.

Inactive Organization-

Drug Highest PhaseApproved

First Approval Date

JP (01 Jul 2004),

HypoalbuminemiaShock, Hemorrhagic

Regulation-

Login to view timeline

Patients diagnosed with Guillain-Barré syndrome were confirmed based on the diagnostic criteria for Guillain-Barré syndrome. Patients who meet all inclusion criteria and do not conflict with the exclusion criteria will receive NPB-01 (intravenous immunoglobulin) 400mg/kg/day for five consecutive days.
Patients evaluate the Functional Grade（FG） and Arm Grade（AG） et al.
As a safety endpoint, the safety of NPB-01 will be investigated the occurrence of adverse events by the start of the study treatment.

Start Date01 Oct 2014

Sponsor / Collaborator

Nihon Pharmaceutical Co., Ltd.

100 Clinical Results associated with Human Normal Immunoglobulin (Nihon Pharmaceutical Co., Ltd.)

Login to view more data

100 Translational Medicine associated with Human Normal Immunoglobulin (Nihon Pharmaceutical Co., Ltd.)

Login to view more data

100 Patents (Medical) associated with Human Normal Immunoglobulin (Nihon Pharmaceutical Co., Ltd.)

Login to view more data

3

Literatures (Medical) associated with Human Normal Immunoglobulin (Nihon Pharmaceutical Co., Ltd.)

01 Jan 1985·Journal of the Japanese Association for Infectious Diseases

Clinical Evaluation of GV-523 for Severe Infections Complicating Hematopoietic Diseases

Article

Author: OYABU, Hiroshi ; TSUDA, Syoichiro ; TAKAHASHI, Isao ; SHIRAI, Tatsuo ; NAGAI, Kiyoyasu ; KURAMOTO, Atsushi ; YASUNAGA, Kojiro ; KAWAGOE, Hiroya ; SAWATA, Hiroyoshi ; KANAYAMA, Yoshio ; FUJIMURA, Kingo ; HASEGAWA, Hirofumi ; SHIBATA, Hirotoshi ; UCHINO, Haruto ; HORIUCHI, Atsushi ; KITANI, Teruo ; ABE, Tatsuo ; YONEZAWA, Tsuyoshi ; TANIGUCHI, Nobuhiro ; KANAMARU, Akihisa ; KIMURA, Ikuro ; MASAOKA, Toru ; KANEKO, Haruo ; KAGEYAMA, Takashi ; OKAMOTO, Yuruko ; HIRATA, Mitsuhiko

01 Jan 1983·Journal of the Japanese Association for Infectious Diseases

Therapeutic Effects of GV-523 on the Severe Infections in Internal and Surgical Clinics

Article

Author: Keimei Mashimo

01 Jun 1974·Jinrui idengaku zasshi. The Japanese journal of human genetics

[Albumin Kyoto, albumin Otsu and albumin Shizuoka-2 (author's transl)].

Article

Author: Nakanishi, K ; Kondo, M ; Nakai, T ; Wada, T ; Yamanoto, M

100 Deals associated with Human Normal Immunoglobulin (Nihon Pharmaceutical Co., Ltd.)

Login to view more data

R&D Status

Approved

10 top approved records.

Login

to view more data

Indication	Country/Location	Organization	Date
Hypoalbuminemia	JP	Nihon Pharmaceutical Co., Ltd.	01 Jul 2004
Shock, Hemorrhagic	JP	Nihon Pharmaceutical Co., Ltd.	01 Jul 2004

Developing

10 top R&D records.

Login

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Hashimoto's Encephalitis	Phase 3	JP	Nihon Pharmaceutical Co., Ltd.	03 Mar 2022
Guillain-Barre Syndrome	Phase 1	JP	Nihon Pharmaceutical Co., Ltd.	01 Oct 2014
AQP4-IgG positive Neuromyelitis optica spectrum disorder	Phase 1	JP	Nihon Pharmaceutical Co., Ltd.	01 May 2013
Multifocal Motor Neuropathy	Phase 1	JP	Nihon Pharmaceutical Co., Ltd.	01 Apr 2013
Polyradiculoneuropathy, Chronic Inflammatory Demyelinating	Phase 1	JP	Nihon Pharmaceutical Co., Ltd.	01 Apr 2013
Pemphigoid, Bullous	Phase 1	JP	Nihon Pharmaceutical Co., Ltd.	01 Aug 2011